FOCR offers path for validating ctDNA as an early endpoint for drug approval

Regulatory NewsRegulatory NewsBiologicsBiotechnologyClinical TrialsDiagnosticsNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy